Selected article for: "current management and risk factor"

Author: Nadim, Mitra K.; Forni, Lui G.; Mehta, Ravindra L.; Connor, Michael J.; Liu, Kathleen D.; Ostermann, Marlies; Rimmelé, Thomas; Zarbock, Alexander; Bell, Samira; Bihorac, Azra; Cantaluppi, Vincenzo; Hoste, Eric; Husain-Syed, Faeq; Germain, Michael J.; Goldstein, Stuart L.; Gupta, Shruti; Joannidis, Michael; Kashani, Kianoush; Koyner, Jay L.; Legrand, Matthieu; Lumlertgul, Nuttha; Mohan, Sumit; Pannu, Neesh; Peng, Zhiyong; Perez-Fernandez, Xose L.; Pickkers, Peter; Prowle, John; Reis, Thiago; Srisawat, Nattachai; Tolwani, Ashita; Vijayan, Anitha; Villa, Gianluca; Yang, Li; Ronco, Claudio; Kellum, John A.
Title: COVID-19-associated acute kidney injury: consensus report of the 25th Acute Disease Quality Initiative (ADQI) Workgroup
  • Cord-id: vgj9piru
  • Document date: 2020_10_15
  • ID: vgj9piru
    Snippet: Kidney involvement in patients with coronavirus disease 2019 (COVID-19) is common, and can range from the presence of proteinuria and haematuria to acute kidney injury (AKI) requiring renal replacement therapy (RRT; also known as kidney replacement therapy). COVID-19-associated AKI (COVID-19 AKI) is associated with high mortality and serves as an independent risk factor for all-cause in-hospital death in patients with COVID-19. The pathophysiology and mechanisms of AKI in patients with COVID-19
    Document: Kidney involvement in patients with coronavirus disease 2019 (COVID-19) is common, and can range from the presence of proteinuria and haematuria to acute kidney injury (AKI) requiring renal replacement therapy (RRT; also known as kidney replacement therapy). COVID-19-associated AKI (COVID-19 AKI) is associated with high mortality and serves as an independent risk factor for all-cause in-hospital death in patients with COVID-19. The pathophysiology and mechanisms of AKI in patients with COVID-19 have not been fully elucidated and seem to be multifactorial, in keeping with the pathophysiology of AKI in other patients who are critically ill. Little is known about the prevention and management of COVID-19 AKI. The emergence of regional ‘surges’ in COVID-19 cases can limit hospital resources, including dialysis availability and supplies; thus, careful daily assessment of available resources is needed. In this Consensus Statement, the Acute Disease Quality Initiative provides recommendations for the diagnosis, prevention and management of COVID-19 AKI based on current literature. We also make recommendations for areas of future research, which are aimed at improving understanding of the underlying processes and improving outcomes for patients with COVID-19 AKI.

    Search related documents:
    Co phrase search for related documents
    • acute kidney injury and adjuvant therapy: 1, 2, 3, 4
    • acute kidney injury and adqi acute disease quality initiative: 1, 2
    • acute kidney injury and local response: 1
    • acute kidney injury and low molecular weight: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • acute kidney injury and low molecular weight heparin: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • acute kidney injury and lung injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39
    • acute kidney injury and lung protective: 1, 2, 3, 4, 5, 6, 7, 8
    • acute kidney injury and lung tissue: 1, 2, 3, 4, 5, 6, 7
    • acute kidney injury and lymphocyte count: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32
    • acute kidney injury and machine patient: 1, 2
    • adaptive innate and adjuvant therapy: 1, 2
    • adaptive innate and local response: 1, 2, 3, 4, 5, 6, 7, 8
    • adaptive innate and low grade inflammation: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18
    • adaptive innate and low molecular weight: 1, 2
    • adaptive innate and low molecular weight heparin: 1
    • adaptive innate and lung injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23
    • adaptive innate and lung protective: 1, 2, 3, 4
    • adaptive innate and lung tissue: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
    • adaptive innate and lymphocyte count: 1, 2